Abstract: Chronic obstructive pulmonary disease (COPD) is associated with smoking but other etiological factors contribute. Chlamydia pneumoniae is an obligate intracellular bacterium causing both acute and chronic respiratory tract infections. Studies have revealed an association between chronic C. pneumoniae infection and COPD, asthma and lung cancer but there have been diffi culties detecting C. pneumoniae in the bronchial tree. Cytospin slides prepared from bronchoalveolar lavage (BAL) fl uid from 14 patients with COPD, 10 healthy smokers (S) and 7 non smokers (NS) were analyzed with a fl uorescein isothiocyanate labeled monoclonal antibody to C. pneumoniae. Lung tissue from 24 patients with advanced emphysema who had undergone lung volume reduction surgery (LVRS) was examined with immunohistochemistry for C. pneumoniae. Archived serum samples for detection of specifi c C. pneumoniae antibodies by microimmunofl uorescence were available for 30 of the BAL subjects and 11 of LVRS patients. C. pneumoniae elementary body like structures were found in 29% of cytospin specimens from COPD patients, 14% of NS and 10% of HS. C. pneumoniae was detected in lung tissue in 8%. COPD patients had higher titres of IgG and IgA than NS and S. There was no association between occurrence of C. pneumoniae in BAL fl uid and antibody titres. In conclusion, the assays used for detection of C. pneumoniae in lung tissue are feasible, and could be adapted in adequately powered studies to further confi rm an association between C. pneumoniae infection and COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) has a signifi cant impact on burden of illness, and WHO predict that by 2020 COPD will be the 5th most prevalent disease worldwide and the 3rd most common cause of death (Lopez et al 1998; Michaud et al 2001) . Tobacco smoking is the major cause of COPD. However, since non-smokers can develop COPD and lung function deterioration continues rapidly in some patients despite smoking cessation, other etiological factors than smoking seem to contribute to the development of the disease. It is likely that both genetic and acquired host factors as well as environmental exposures, either separately or in combination may contribute to the development of the disease.
Chlamydia pneumoniae, an obligate intracellular bacterium with a unique biphasic replicative cycle, is an established cause of acute and chronic upper and lower respiratory tract infections. During the replicative cycle, C. pneumoniae presents as infectious elementary bodies and metabolically active intracellular reticulate bodies. Release of pro-infl ammatory cytokines in response to a chronic C. pneumoniae infection could potentially amplify infl ammation and damage of the lungs caused by cigarette smoke. Several studies have demonstrated persistent elevated titres of specifi c IgA antibodies to C. pneumoniae in patients with COPD (von Hertzen et al 1996; von Hertzen et al 1997) , and we recently reported that serology suggestive of chronic C. pneumoniae infection was an independent risk factor for the development of COPD (Brandén et al 2005) . Further, macrophages in lung tissue from patients with COPD have been reported to stain positive for C. pneumoniae LPS (Rupp et al 2004) , and C. pneumoniae has also been detected in lung tissue from subjects with COPD (Wu et al 2000) .
The two major components of airways obstruction in COPD are small airways disease and emphysema, which both to a large extent are irreversible and cause permanent reduced lung function. Samples from these peripheral compartments of the lung can be obtained by bronchoalveolar lavage (BAL), and the present study was conducted to evaluate the usefulness of BAL fl uid cytospin preparations for the detection of C. pneumoniae. Further, we examined lung tissue from patients with advanced emphysema undergoing lung volume reduction surgery (LVRS) in order to evaluate the association between C. pneumoniae and severe COPD.
Material and methods

Study population
The investigated subjects were recruited in two separate studies. Both were approved by the Ethics Committee, Karolinska University Hospital, and informed consent was given by all patients.
Study A
Study A was performed April 2000 to June 2004, and included 31 subjects; 14 with stable clinical COPD without any exacerbations for the last 3 months, and as controls 10 healthy smokers and 7 non-smokers with normal chest radiographs (Table 1) . They consist of a sub-group of subjects from a previous study (Lofdahl et al 2005) where cytospin preparations from BAL were available. All subjects underwent spirometry and bronchoscopy with BAL, and the cells were concentrated on glass slides using a cytospin procedure. Analysis of specifi c C. pneumoniae antibodies in serum taken prior to bronchoscopy was performed in all subjects except one.
Study B
Study B included 24 patients (15 females and 9 males), who had undergone LVRS for severe emphysema between January 1995 and May 2001. Six patients were homozygote for α 1 -antitrypsin defi ciency (4 females and 2 males), 3 were heterozygote (1 female and 2 males) and the other 15 had normal enzyme levels. The mean age was 61.6 years (SD 7.7). All were ex-smokers except one homozygote female. Information on the smoking habits was based on medical records, and the information was not suffi cient to enable calculations in three subjects. Mean smoking pack-years (PY; product of years smoking and the number of cigarettes smoked per day divided by 20) 27.5 (SD 17.2). Spirometries were performed in all, and mean forced expired volume in one second (FEV 1 ) was 23.8 (SD 4.8) % predicted. Reversibility was tested in all except two, and demonstrated in mean 3.3 (SD 3.4) % predicted. C. pneumoniae serology was available for 11 of the patients. Samples were collected taken at time of surgery in 7 patients, and 2-7 years post surgery in 4 patients.
Lung function tests
Lung function was determined by the use of dynamic spirometers, in Study A Vitalograph Compact (Vitalograph Ltd, Buckingham, UK) and in Study B Gould 2400 (Gould Electronics, Netherlands). The procedures were performed in a standardized manner, and the results for forced vital capacity (FVC), vital capacity (VC) and forced expiratory volume in one second (FEV 1 ) were expressed as percentage of predicted values (Quanjer 1983; Quanjer et al 1993) . Reversibility of airways obstruction was tested by measuring FEV 1 before and 10 min after inhalation of bronchodilators; in Study A one mg terbutaline (Bricanyl Turbuhaler; AstraZeneca) and in Study B nebulisation of 5 mg salbutamol (Ventoline; GlaxoSmithKline) and 0.25 mg ipratropium bromide (Atrovent; Boehringer Ingelheim), and was calculated as improvement of FEV 1 in percentage of predicted FEV 1 .
Bronchoscopy and bronchoalveolar lavage (BAL)
Bronchoscopy was performed on an outpatient basis after overnight fasting. Following pre-medication with morphin-hyoscine i.m. 45 min prior to the investigation, the bronchoscope (Olympus F Type P30, Olympus Optical Co, Ltd, Tokyo, Japan) was inserted nasally after topical anesthesia with lignocaine (Xylocain; AstraZeneca, Södertälje, Sweden). BAL was performed by wedging the bronchoscope in a sub-segment of the middle lobe. In one of the COPD patients BAL was performed in one of the basal sub-segments of the right lower lobe due to diffi culties in wedging the bronchoscope in the middle lobe. Five aliquots of 50 ml of sterile phosphate buffered saline (PBS) adjusted to 37 °C were instilled and gently suctioned back with a negative pressure of −40 to -50 mm Hg. Dwell time was kept to a minimum as recommended by the European Respiratory Society task force (Haslam et al 1999) . The procedure was interrupted if the recovery after 150-200 ml of instilled fl uid was Ͻ35 ml or in case of persistent cough or hypoxia to Ͻ90% oxygen saturation despite appropriate oxygen supplement. The BAL fl uid was collected in a silicone treated bottle kept on ice, which was immediately transported to the laboratory. The fl uid was fi ltered through a Dacron membrane (Millipore, Cork, Ireland) and centrifuged onto microscope slides at 400x g for 10 min at 4 °C, then frozen at -80 °C.
Lung volume reduction surgery
Surgery was performed by median sternotomy except for a few cases in which thoracotomy was done. The most damaged areas were removed with an ambition to reduce the lung volume with 30%.
Detection of C. pneumoniae in study A
Detection of C. pneumoniae was performed by direct fl uorescence antibody technique (DFA) on cytospin preparations of BAL fl uid. The cytospin specimens on glass microscope slides were fi xed in cold acetone for 15 minutes and dried in air. Twenty-fi ve microliters of a monoclonal antibody directed against C. pneumoniae (Imagen TM Chlamydia pneumoniae, DAKO Ltd, Cambridgeshire, UK) was overlaid on each specimen, and slides were incubated at 37 °C for 30 min in a moist chamber. Positive and negative control slides were included in all runs. Slides provided in the Imagen kit containing C. pneumoniae infected cells served as positive controls, and C. pneumoniae infected cells incubated with a fl uorescein isothiocyanate labeled adenovirus monoclonal antibody were used as negative controls. Washing with gentle agitation was done with PBS pH 7.5 for 5 minutes, after which the slides were dried in air, mounted, coverslipped and examined immediately using an UV microscope (Olympus B × 40) at 500x magnifi cation. The presence of bright apple-green fl uorescing round bodies concomitant in size with elementary bodies were considered as possible positive fi ndings for C. pneumoniae.
Detection of C. pneumoniae in study B
Immunohistochemistry (IHC) for C. pneumoniae was performed with the patient identity blinded. Formalin fi xed lung tissue was embedded in paraffi n and cut at a thickness of 4 μm. The sections were placed on glass slides and deparaffi nized according to standard procedure including clearing with xylene × 2, and hydrated through a series of alcohols with decreasing concentrations. The sections were overlaid with 0.5% pepsin (Sigma Chemical Co, St. Louis, Mo) to open up the cells and incubated for 15 minutes at 37 °C. After washing with PBS-Tween 20 (PBST) at pH 7.6 × 2 for 5 minutes, peroxidase blocking reagent (DAKO Corporation, Carpinteria, CA) was overlaid, and the slides were incubated for 15 minutes at room temperature in a moist chamber. Washing was done twice for 5 minutes in PBST and universal blocking solution (Dako Diagnostics Canada Inc, Mississauga, ON) was overlaid and incubated for 15 min at room temperature. The slides were gently drained and a 1:5 dilution of mouse monoclonal antibody to Chlamydia pneumoniae RR-402 (DakoCytomation Ltd, Ely, UK) in antibody diluting buffer (DAKO Diagnostics Canada Inc., Mississauga, ON) was added. Slides were incubated overnight at 4 °C and then washed twice with PBST. StreptABComplex/HRP Duet, Mouse/Rabbit (Dako A/S, Glostrup, Denmark) was used for the streptavidin/biotin reaction using a biotinylated goat antibody to mouse and rabbit immunoglobulin, streptavidin and a biotinylated horseradish peroxidase. Finally, DAKO AEC Substrate System (DAKO Corporation, Carpinteria, CA) was used for visualization of the red coloured Chlamydia antigen in the tissue sections. Tissue sections previously obtained from patients with lung cancer and proven C. pneumoniae infection were used as positive controls. As negative controls an antibody to mouse IgG3 (NeoMarkers, Fremont, CA), the same class of antibody as the RR-402 monoclonal, was used in all runs.
Serology for C. pneumoniae
C. pneumoniae antibodies were analyzed by microimmunofl uorescence (MIF) at an accredited clinical microbiology laboratory using a previously standardized procedure Gnarpe, Sparr et al 2000) . All sera were separated from erythrocytes upon arrival at the laboratory and frozen at -20 °C until tested. Sera were diluted 1:32 with PBS at pH 7.4 and tested for IgG and IgA antibodies using 21-well antigen slides with elementary bodies of C. psittaci, C.trachomatis and C. pneumoniae in each test well (LabSystems Oy; Helsinki, Finland).
Sera found to be positive in a 1/64 screening dilution for IgG were re-diluted and tested in doubling dilutions to endpoint. All positive sera were retested and sera positive for IgA were absorbed with Gullsorb (Gull Laboratories Ltd, USA) to remove IgG before dilution, and then tested in doubling dilutions. Serum dilutions were incubated with antigens for 14-16 h at 4 °C at all testing occasions. This prolonged incubation at 4 °C increases the sensitivity of the test: a 1/32 dilution of serum incubated overnight is equivalent to a titer of 1/8-1/16 when incubated for 30-60 min in a conventional MIF test. Slides were washed thoroughly in three changes of PBS solution (pH 7.4), then incubated with fl uorescein isothio-cyanate-conjugated rabbit antihuman IgG or IgA (Dakopatts; Glostrup, Denmark) at 37 °C for 30 min. Control sera with specifi ed high and low titres were used on each testing occasion, and tests were accepted only if the titres were within one dilution step of the predetermined mean titres for the respective quality control sera. An experienced microbiologist read all tests with an UV microscope (Zeiss; Jena, Germany) using a 40x oil immersion lens and a 10x ocular lens (total magnifi cation, x400).
Statistical analysis
Statistical analyses were only performed in Study A. Comparisons between the groups were performed by analysis of variance, and in case of statistical signifi cance (p Ͻ 0.05), post-hoc analysis was performed with the LSD test. Analyses of difference in serological titres were performed after logarithmic transformation, and negative observations were assigned a number corresponding to one titre step below the detection level.
Results
Study A
C. pneumoniae species (apple green elementary body like structures) were detected with DFA on cytospin slides from BAL fl uid in 29% of the COPD patients, 10% of the healthy smokers and 14% of the never-smokers (Table 1 and Figure 1 ). No inclusion bodies in the cells were observed on the cytospins. The specifi c IgG-antibody titres were signifi cantly higher in the COPD patients than in the healthy smokers and non-smokers (Figure 2 ). The prevalence of specifi c IgG antibody titre Ն1/128 were 64% in the COPD patients, 30% in the smokers and 33% in the never-smokers. Corresponding fi gures for specifi c IgA-antibody titre Ն1/64 were 29%, 10% and 17%. None of the differences between the groups was statistically significant. There was no correlation between high antibody titres and detection of the C. pneumoniae elementary bodies in the cytospin preparations.
Study B
No signs of infl ammation were observed in the majority of lung tissue samples from the subjects with advanced emphysema. C. pneumoniae was detected with IHC in lung tissue from 2 of 24 patients with advanced emphysema, one female with α 1 -antitrypsin deficiency who had never smoked and one male ex-smoker with normal α 1 -antitrypsin level. Serology for C. pneumoniae antibodies was not available for these two individuals. For those subjects where sera for antibody analyses were available, specifi c IgG-antibodies titres Ն1/128 were detected in 55% and IgA titres Ն1/64 in 36% of the subjects. In those where sera were available at the time of surgery 57% had IgA titres Ն1/64.
Discussion
In this study we demonstrated that C. pneumoniae elementary body like structures could be detected in cytospin preparations of BAL fluid with a higher, although not statistically signifi cant, prevalence in subjects with COPD than in healthy smokers and non-smokers. Further, the specifi c IgG and IgA antibody titres were higher in subjects with COPD than in healthy smokers and non-smokers. We have also shown that C. pneumoniae could be detected in lung tissue from 2 of 24 subjects undergoing surgery for severe emphysema.
Sero-epidemiological studies have demonstrated that C. pneumoniae is a common and widespread pathogen with 50% of adults in the general population having detectable IgG antibody titres (Grayston 1989) . This was confi rmed in the present study, which demonstrated a high prevalence (71%) of IgG titres Ն1/64. Several studies have shown an association between chronic C. pneumoniae infection defi ned by serological criteria and COPD (von Hertzen et al 1996; von Hertzen et al 1997; Smieja et al 2002; Brandén et al 2005; Kurashima et al 2005) . This study confi rms such an association, since subjects with COPD had signifi cantly higher specifi c IgG titres than healthy individuals with a similar smoking history. The persistence of elevated titres of short-lived IgA has been proposed as a marker for chronic, recurrent or active carrier state (Saikku et al 1992) . Chronic C. pneumoniae infection is thus strongly indicated in case of elevated specifi c IgA levels in paired serum samples taken with an extended interval. Since our study did not include repeated serological investigations, the results must be interpreted with caution, since a single elevated value can represent an acute infection. However, none of the subjects showed any signs of respiratory infection at the time of the investigation. In this study a larger proportion of subjects with COPD than healthy smokers and non-smokers had IgA titres Ն1/64, but the difference was not statistically signifi cant.
Although the association between serological signs of chronic C. pneumoniae infection and COPD is well established, knowledge about the host cells and tissues for the infection is limited. It has been reported that COPD patients are more likely to have C. pneumoniae DNA in peripheral blood mononuclear cells than patients undergoing coronary angiography (Smieja et al 2002) , and there are several publications demonstrating an association between C. pneumoniae and atherosclerosis (Saikku et al 1988; Muhlestein et al 1996; Campbell et al 1998) . To strengthen a causal relationship with COPD, presence of the microorganism should ideally be demonstrated in lung tissue. C. pneumoniae can be detected by a number of methods such as immunohistochemistry, PCR (polymerase chain reaction) on lung tissue and culture of fresh tissues. We only analyzed the specimens with immunohistochemistry, and due to lack of good specimens we could unfortunately not verify the fi ndings with other methods.
C. pneumoniae has previously been identified in emphysematous tissue (Wu et al 2000; Rupp et al 2004; Theegarten et al 2004) , and we could confi rm the presence of C. pneumoniae in lung tissue from two out of 24 subjects who had undergone lung volume reduction surgery due to severe emphysema. The detection rate corresponds with the fi ndings in two of the previously reported studies (Rupp et al 2004; Theegarten et al 2004) , but was considerably lower than in another study (Wu et al 2000) . However, in Wu's study archival tissue from subjects who had undergone lobectomy for bronchial carcinoma was analyzed, and this could have infl uenced the results. Several studies have reported an association between chronic C. pneumoniae infection and lung cancer (Laurila et al 1997; Jackson et al 2000; Koyi et al 2001; Kocazeybek 2003) , and the organism has been detected in macrophages close to the lung cancer using the same staining techniques as in the present study (Koyi et al 2001) .
The low rate of detection of C. pneumoniae in emphysematous tissue in this and other studies may be explained by the patchy localization of the infection (Kuo 2000) , and that the investigated tissue samples only represent a very limited part of the lungs. BAL covers a larger compartment including small airways, which are affected in COPD. The retained BAL fl uid can either be used for cultivation or for identifi cation of micro-organisms with immunological methods. Cultivation of C. pneumoniae is diffi cult, and tissue specimens should undergo primary isolation procedures plus 4-6 additional passages (Dowell et al 2001) . Since this was a retrospective study, freshly procured samples were not available for cultivation, and we used immunological techniques with monoclonal antibodies for detection of the micro-organism on fi xed cytospin preparations.
C. pneumoniae has previously been detected by DFA on buffy coat cell pellets from BAL of children with asthma and other lung diseases (Webley et al 2005) , but to our knowledge, no previous study has aimed to detect C. pneumoniae from BAL fl uid cytospin preparations. Using DFA, we found elementary body like structures on cytospin slides in four subjects with COPD, in one healthy smoker and in one non-smoker. As the specimens were archival we had no possibility to confi rm the identity of these structures. It is known that some bacteria, like Staphylococcus aureus containing Protein A can unspecifi cally bind the FITC-labeled antibody and cause false positive results, but this bacterium should not be present in the lung and the organisms are usually larger than the elementary body of C. pneumoniae. Further analysis with other techniques such as PCR are needed to confi rm the identifi cation of C. pneumoniae. However, our fi nding of elementary body like structures in cytospin preparations from BAL is interesting, and if confi rmed, could add information on an association between C. pneumoniae infection and COPD. Appropriately designed and powered studies are needed to confi rm this fi nding.
A disadvantage of studying BAL in COPD is that the recovery of fl uid often is low (Linden et al 1993; Soler et al 1999) , which also was seen in this study. This might infl uence the reliability of the sampling, since in case of low recovery the BAL fl uid may not ideally represent the distal bronchial tree but rather refl ect conditions in large airways.
Long term studies using C. pneumoniae serology are needed to reveal whether chronic infections initiate the development of COPD or occur as a consequence of reduced immune response in a compromised lung. To further strengthen a causal relationship between chronic infections and COPD, the bacteria should ideally be identifi ed in the lungs. Although this study was not powered to confi rm an association between C. pneumoniae infection and COPD, we have demonstrated that the assays used for detection of the organism in cytospin from BAL and resected lung tissue are feasible, and thus could be adapted in adequately sized studies.
